Comparison

AOD-9604Tesamorelin

Both relate to the GH axis but act through different mechanisms. AOD-9604 is the modified 176-191 fragment from the C-terminus of growth hormone — purely lipolytic. Tesamorelin is a stabilized GHRH analog — it stimulates the pituitary to release endogenous GH.

Spec	A AOD-9604	B Tesamorelin
Mechanism	GH C-terminal fragment → β3-AR lipolysis	GHRH analog → endogenous GH pulse
Origin	Monash University (Frank Ng, 1990s)	Theratechnologies (Canada)
FDA status	Phase IIb (Metabolic Pharmaceuticals 2007); discontinued	Approved (Egrifta, 2010) — HIV lipodystrophy
IGF-1 effect	No — no mitogenic signal	Yes — IGF-1 elevation
Effect on blood glucose	No hyperglycemia	May elevate blood glucose
Dosing	250-500 mcg s.c. fasted	1-2 mg s.c. daily
Half-life	~30 minutes	~26 minutes

Choose A when

AOD-9604

Pure lipolysis research without metabolic side effects. Cheaper and pairs cleanly with GHRP/GHRH stacks.

See full profile

Choose B when

Tesamorelin

Selective visceral fat reduction with FDA approval and 26-week clinical data.

See full profile

Verdict

Different tools for different goals. AOD-9604 is purely lipolytic; Tesamorelin is a true GH stimulator. Not interchangeable.

Frequently asked

What people ask

Can AOD-9604 and Tesamorelin be stacked?

Yes, without significant overlap. AOD-9604 covers pure lipolysis; Tesamorelin stimulates endogenous GH with pulsatile signaling. The two mechanisms are complementary.

Other comparisons

Keep exploring

Semaglutide vs Tirzepatide

Semaglutide vs Retatrutide

Tirzepatide vs Retatrutide

BPC-157 vs TB-500

Last reviewed: 6 May 2026by PeptidLabs Editorial

Comparison

AOD-9604Tesamorelin

Spec	A AOD-9604	B Tesamorelin
Mechanism	GH C-terminal fragment → β3-AR lipolysis	GHRH analog → endogenous GH pulse
Origin	Monash University (Frank Ng, 1990s)	Theratechnologies (Canada)
FDA status	Phase IIb (Metabolic Pharmaceuticals 2007); discontinued	Approved (Egrifta, 2010) — HIV lipodystrophy
IGF-1 effect	No — no mitogenic signal	Yes — IGF-1 elevation
Effect on blood glucose	No hyperglycemia	May elevate blood glucose
Dosing	250-500 mcg s.c. fasted	1-2 mg s.c. daily
Half-life	~30 minutes	~26 minutes

Choose A when

AOD-9604

Pure lipolysis research without metabolic side effects. Cheaper and pairs cleanly with GHRP/GHRH stacks.

See full profile

Choose B when

Tesamorelin

Selective visceral fat reduction with FDA approval and 26-week clinical data.

See full profile

Verdict

Different tools for different goals. AOD-9604 is purely lipolytic; Tesamorelin is a true GH stimulator. Not interchangeable.

Frequently asked

What people ask

Can AOD-9604 and Tesamorelin be stacked?

Yes, without significant overlap. AOD-9604 covers pure lipolysis; Tesamorelin stimulates endogenous GH with pulsatile signaling. The two mechanisms are complementary.

Other comparisons

Keep exploring

Semaglutide vs Tirzepatide

Semaglutide vs Retatrutide

Tirzepatide vs Retatrutide

BPC-157 vs TB-500

Last reviewed: 6 May 2026by PeptidLabs Editorial